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Lack of major involvement of human uroplakin genes in vesi-
coureteral reflux: Implications for disease heterogeneity.
Background. Primary vesicoureteral reflux (VUR) is a hered-
itary disorder characterized by the retrograde flow of urine into
the ureters and kidneys. It affects about 1% of the young chil-
dren and is thus one of the most common hereditary diseases.
Its associated nephropathy is an important cause of end-stage
renal failure in children and adults. Recent studies indicate that
genetic ablation of mouse uroplakin (UP) III gene, which en-
codes a 47 kD urothelial-specific integral membrane protein
forming urothelial plaques, causes VUR and hydronephrosis.
Methods. To begin to determine whether mutations in UP
genes might play a role in human VUR, we genotyped all four
UP genes in 76 patients with radiologically proven primary
VUR by polymerase chain reaction (PCR) amplification and
sequencing of all their exons plus 50 to 150 bp of flanking in-
tronic sequences.
Results. Eighteen single nucleotide polymorphisms (SNPs)
were identified, seven of which were missense, with no trun-
cation or frame shift mutations. Since healthy relatives of the
VUR probands are not reliable negative controls for VUR, we
used a population of 90 race-matched, healthy individuals, unre-
lated to the VUR patients, as controls to perform an association
study. Most of the SNPs were not found to be significantly as-
sociated with VUR. However, SNP1 of UP Ia gene affecting a
C to T conversion and an Ala7Val change, and SNP7 of UP III
affecting a C to G conversion and a Pro154Ala change, were
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marginally associated with VUR (both P = 0.08). Studies of
additional cases yielded a second set of data that, in combina-
tion with the first set, confirmed a weak association of UP III
SNP7 in VUR (P = 0.036 adjusted for both subsets of cases vs.
controls).
Conclusion. Such a weak association and the lack of families
with simple dominant Mendelian inheritance suggest that mis-
sense changes of uroplakin genes cannot play a dominant role
in causing VUR in humans, although they may be weak risk
factors contributing to a complex polygenic disease. The fact
that no truncation or frame shift mutations have been found in
any of the VUR patients, coupled with our recent finding that
some breeding pairs of UP III knockout mice yield litters that
show not only VUR, but also severe hydronephrosis and neona-
tal death, raises the possibility that major uroplakin mutations
could be embryonically or postnatally lethal in humans.
Primary, nonsyndromic, vesicoureteral reflux (VUR;
OMIM, 193000) is characterized by the retrograde flow
of urine from the urinary bladder to the ureters and kid-
neys. This congenital anomaly affects about 1% of young
children and is thus one of the most common congeni-
tal anomalies affecting humans [1]. VUR is thought to
be associated with the abnormally lateral insertion of the
ureters into the bladder leading to an enlarged ureteral
orifice and a shortening of the segment of the ureter,
which normally traverses obliquely through the bladder
wall. Individuals with VUR are prone to urinary tract in-
fection (UTI); indeed, up to 30% of children presenting
with such infections have VUR [1]. The reflux of infected
urine into the kidney can cause acute pyelonephritis and
subsequent scarring; such “reflux nephropathy” is an
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important cause of end-stage renal failure in both chil-
dren and adults, accounting for 10% to 15% of all patients
who require long-term dialysis and/or renal transplanta-
tion [2, 3].
VUR has a strong hereditary component, with a 30- to
50-fold increase in incidence in first-degree relatives of
VUR probands [4–7]. Indeed, systematic screening with
micturating cystography of young, first-degree relatives
of VUR index cases has revealed that up to 50% of sib-
lings and offspring are affected by VUR [5, 6]. Other
investigators have identified several kindreds with domi-
nant inheritance of VUR and associated neprhopathy [8,
9]. As some of the kidney damage associated with VUR
is secondary and hence potentially preventable by pro-
phylactic antibiotic treatment and/or surgical interven-
tion, there is a clear need for the early detection of this
condition. In addition, currently VUR is definitely diag-
nosed in young children by voiding cystourethrography
or direct radionuclide micturating cystography, which are
invasive and costly; the identification of genes involved
in VUR could lead to the development of genetic screen-
ing for infants. Feather et al [9] has demonstrated that
some families link to a locus on 1p13; however, the same
study demonstrated that VUR was genetically heteroge-
neous, with two families clearly not mapping to that locus.
Furthermore, the significance of these results to a wider
population of patients with VUR is unknown. A poten-
tial complicating factor in genetic studies of the disorder
is the well-established tendency for VUR to regress in the
first two decades of life [3]; hence, apparently disease-free
or asymptomatic relatives of VUR probands should not
be classified as “normal” in association or segregation
analyses.
We have recently shown that genetic ablation of uro-
plakin III (UP III) caused VUR in mice [10]. Uroplakins
(UP) are a group of four membrane proteins that are syn-
thesized as major differentiation products by mammalian
urothelium, the lining of most of the lower urinary tract,
including proximal urethra, bladder, ureter, and renal
pelvis. The four UPs [i.e., UP Ia (27 kD), UP Ib (28 kD),
UP II (15 kD), and UP III (47 kD)] are highly conserved
in all mammalian species examined so far, including hu-
mans [11–16]. These integral membrane proteins form
16 nm particles that are packed hexagonally forming two-
dimensional crystals (“urothelial plaques”) that cover
almost the entire apical surface of superficial urothe-
lial umbrella cells [17–21]. Nearest-neighbor analysis by
chemical crosslinking showed that UP Ia and UP Ib,
which are 40% identical and belong to the “tetraspanin”
supergene family [22–24], are crosslinked selectively to
UP II and UP III, respectively, suggesting that the four
uroplakins form two pairs (consisting of UP Ia/UP II and
UP Ib/UP III [25–27]). Ablation of UP III led to major
changes in urothelial morphology and function, including
the absence of a typical superficial umbrella cell layer;
reduction of apical urothelial plaque size; compromised
urothelial function as a permeability barrier; and, inter-
estingly, VUR in 50% to 60% of the mice of both genders,
sometimes associated with hydronephrosis [10, 28]. These
results provide direct proof that UP proteins are subunits
of urothelial plaques and that UP III contributes to the
formation of urothelial permeability barrier [10, 28].
To determine whether mutations in UP genes might
play a role in human VUR, we genotyped all four UP
genes in a population of 76 VUR patients and found
18 single nucleotide polymorphisms (SNPs), seven of
them missense. Since symptom-free relatives of the VUR
probands are not reliable negative controls for VUR [29],
we used 90 race-matched healthy individuals, unrelated
to the VUR patients, as controls to study the association
of these SNPs with VUR. We found only a weak asso-
ciation between two UP polymorphisms with VUR sug-
gesting that missense changes of UP genes cannot play
a dominant role in causing VUR in humans, although
they may be weak risk factors contributing to a complex
polygenic disease.
METHODS
Subjects
The patients and their family members were assessed
by pediatric and adult urologists and/or nephrologists,
and the inclusion of patients for studies was approved
by the Institutional Review Boards of the various partic-
ipating groups. Patients who presented to the pediatric
urology clinic with a presumptive diagnosis of reflux, as
determined by a febrile urinary tract infection (UTI),
recurrent infections, or moderate to severe hydronephro-
sis had a full work-up with a cystogram. Either a fluoro-
scopic or radionuclide voiding cystogram were performed
by infusing radiocontrast or radionuclide material into
the bladder through a catheter. Demonstration of the
contrast agent or radiotracer material into the ureters
and renal pelvis confirmed the diagnosis of reflux. VUR
had been diagnosed in all patients, except those included
in the Newcastle-upon-Tyne group, using micturating
cystourethrograms or, in some girls, by radionucleotide
cystography. The patients included in the Newcastle-
upon-Tyne group were mainly assessed as adults and had
typical appearances of reflux nephropathy on intravenous
pyelogram; the characteristics of this group have been de-
scribed in detail before [30]. Patients who had evidence
of secondary causes of VUR (e.g., structural bladder out-
flow obstruction) or other complicating clinical features
(e.g., complex multiorgan syndromes with VUR, such
as the renal-coloboma syndrome [29]) were excluded
from this study. Of the 76 VUR patients (from Pitts-
burgh, New York, and London) who we used for detect-
ing polymorphisms of UP genes, 59 were probands from
the same number of families affected by more than one
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member with VUR and 17 were apparently sporadic
cases; the additional 167 patients (from Boston and
Newcastle-upon-Tyne) were all probands of the same
number of families. In the association study, the “con-
trols” were race-matched, healthy individuals unrelated
to the VUR patients; this is an “unselected” normal popu-
lation that were not screened and therefore ∼1% of them
would be expected to have VUR. Informed consent was
obtained from individuals before they were included in
the study. Total genomic DNA was purified from periph-
eral blood leukocytes using a blood DNA extraction kit
(Qiagen; Valencia, CA, USA).
Genomic structure of the human UP genes
The genomic structure of the coding sequence of hu-
man uroplakin genes was determined by aligning cDNA
and genomic sequences. A search of the human genome
sequence in NCBI database using four human UP cDNA
sequences (GenBank accession no. AF085807 for UP
Ia; AB002155 for UP Ib; NM 006760 for UP II; and
NM 00695 for UP III) yielded the following genomic
sequences containing uroplakin genes: overlapping cos-
mids with GenBank accession number AC002115 (UP
Ia), BAC RP11-484M3 (UP Ib), BAC RP11-110I1 and
RP11-158I9 (UP II), and BAC CTA-268H5 (UP III).
These genomic sequences were used to determine the
exon/intron junctions of the UP genes.
Immunohistochemical staining
Terminated human embryonic tissues at 65 and 70 days’
gestation were collected with full ethical approval and
were provided by the Wellcome Trust/Medical Research
Council Human Embryo Bank held at the Institute of
Child Health, London. Bladders were collected from
Balb/c mice at different developmental stages. Paraffin
sections were deparaffinized, microwaved, and stained
using rabbit antisera to total bovine UPs, mouse mono-
clonal antibodies, or to synthetic peptides of individual
UPs [10, 25].
Polymorphism detection
Based on the exon/intron junctions, we designed
primers (see Results section) to amplify all human UP ex-
ons and 50 to 150 bp of their flanking intronic sequences.
Polymerase chain reaction (PCR) reactions were per-
formed in a total reaction volume of 30 lL containing
50 mmol/L Tris-HCl (pH 9.1), 16 mmol/L ammonium
sulfate, 3.5 mmol/L MgCl2, 4.5 lg bovine serum albu-
min (BSA), 6 pmol of each primer and 0.2 mmol/L de-
oxynucleoside triphosphate (dNTP), plus 20 ng genomic
DNA and 1 U Taq DNA polymerase. PCR was initiated
with a denaturation step of 95◦C for 4 minutes, followed
by 35 cycles of 20 seconds at 94◦C, 30 seconds at 60◦C,
Table 1. Chromosomal location of uroplakin (UP) genes
Ia Ib II III
Bovine 18 1 15 5 or 6
Mouse 7 16B5-C2 9 15E2-E3
Human 19q13.1 3q13.3-q21 11q23 22q13.2–13.3
and 1 minute at 72◦C, and a final 10-minute extension
at 72◦C. PCR products were treated using a presequenc-
ing kit (USB, Cleveland, OH), and sequenced using a Big
Dye Terminator kit (Applied Biosystem, Foster City, CA,
USA). For the specific sequencing primers see Table 2.
Sequence variants were identified using the Sequencher
3.1 software (GeneCodes, Ann Arbor, MI, USA).
Statistical methods
Chi-square tests (or Fisher exact tests) were used to
compare the distributions of genotype frequencies for
each of the six polymorphisms of interest (UP Ia A7V,
S31A, and M255T; UP Ib R113Q; UP III -73A/G and
P154A) individually in the VUR group compared with
the control group. Odds ratios for each homozygous
genotype relative to the heterozygous genotype were es-
timated for the case compared with the control group
with 95% confidence intervals. These analyses were con-
ducted separately for the first 76 VUR patients and 90
healthy individuals (batch 1) and the additional 167 VUR
patients and 60 normal subjects (batch 2). In addition, for
the SNP with replication (two batches), the analyses were
conducted adjusted for batch using the Mantel-Haenszel
test [31]. All P values were two-sided. No adjustments
were made for multiple comparisons.
RESULTS
Chromosomal location, exon-intron junctions,
and expression of human UP genes
We have previously mapped the chromosomal location
of several UP genes in mouse, cattle and human. The cat-
tle genes were mapped through their segregation in a
panel of (bovine × rodent) somatic cell hybrids [32]. The
mouse genes were mapped by analyzing the inheritance
of restriction fragment length variants in recombinant in-
bred mouse strains, and by fluorescence in situ hybridiza-
tion (FISH) analysis [32, 33]. Subsequent data from FISH
analyses [34] and human genomics assigned human UP
Ia, UP Ib, UP II, and UP III genes to 19q13.1, 3q13.3-
q21, 11q23, and 22q13, respectively (Table 1). Since the
genomic sequences of the four major human uroplakin
genes are already completed, their intron/exon bound-
aries were determined by the alignment of the cDNA and
genomic sequences (Fig. 1) (Table 2). Studies of mouse
and human embryonic bladder tissues by immunohisto-
chemical staining indicated that UP genes were expressed
Jiang et al: Lack of major involvement of human uroplakin genes in VUR 13
Fig. 1. Genomic structure of human genes encoding uroplakins (UPs)
Ia, Ib, II, and III. Boxes and lines denote exons and introns, respectively.
The numbers above each gene denote the detected single nucleotide
polymorphisms (SNPs). Human UP Ia, UP Ib, UP II, and UP III genes
span about 11.6, 18.5, 2.2,and 10.9 kb, respectively.
in mouse fetal bladder urothelium as early as day 13 gesta-
tion (Fig. 2A to E), and in human fetal bladder urothelium
as early as 65 to 70 days gestation (Fig. 2F to I).
Association study of UP SNPs and VUR
We genotyped the four human UP genes in 76 VUR
subjects by PCR amplification of the 25 exons (∼5.2 kb of
amplified exonic sequences per individual) and their 50 to
150 bp of flanking intron sequences (∼4.4 kb intronic se-
quences per individual); see Table 3 for the intronic and
other PCR primer sequences). Sequencing of the PCR
products (totaling ∼10 kb per individual) revealed 18
SNPs (Table 4). Of these, seven polymorphisms in exons
resulted in substituted amino acids (Ala7Val, Ser31Ala,
Tyr251Phe/Cys, and Met255Thr for UP Ia; Arg113Gln
for UP Ib; and Gln91Leu and Pro154Ala for UP III);
six other polymorphisms in the exons did not change the
amino acid sequence and were thus silent; and five were
in noncoding regions (Table 4). Although we could not
rule out the possible deletion of an entire allele in samples
showing apparent homozygosity, no frame-shift mutation
or truncation was detected in any of the VUR samples.
In the controls we focused on the genotype of SNPs that
cause amino acid substitutions as well as those residing
in the 5′-promoter region, because mutations in these re-
gions were more likely to be functionally significant than
those that were silent or were in the noncoding introns.
SNPs with a minor allele frequency of <5% were not
analyzed due to insufficient statistical power. Based on
these criteria, we compared the genotype frequency of
three SNPs of UP Ia (SNPs 1, 2, and 6), one of UP Ib
(SNP 1), and two of UP III (SNPs 1 and 7), in our con-
trol and VUR groups (Table 5). The results show that
the genotype frequencies of UP Ia SNPs 2, 6, UP Ib SNP
1, and UP III SNP1 of VUR were not significantly dif-
ferent from the control group (Table 5). The only SNPs
for which the distributions of genotypes were marginally
different between the control and VUR groups were the
SNP 1 of UP Ia and SNP 7 of UP III (both with P = 0.08).
We further analyzed the SNP 7 of UP III, which caused
a proline-to-alanine change, by PCR-direct sequencing
and by PCR-restriction enzyme digestion, using a second
batch of additional 60 normal and 167 cases of VUR. The
UP III SNP 7 was characterized by a C to G conversion
leading to the mutation of proline 154, which is highly
conserved in mouse, rabbit, pig, bovine and human UP III
in 145-DPNF(Q/R)GLCNPL(S/T)AATEYRFKYVLV-
169. The minor G allele was present in 15.7% of 150
normal individuals but in 23.3% of 243 VUR patients.
Although the two batches of samples yielded some-
what different results possibly reflecting the heterogene-
ity/selection of the patient population (see Discussion
section), the genotype frequencies of the control group
(G/G at 2%, G/C at 28%, and CC at 70%) were signifi-
cantly different from those of the VUR population (G/G
at 6.2%, G/C at 34.2%, and CC at 59.6%) (Table 5; P =
0.036 in combined data; adjusted for batch using the
Mantel-Haenszel test). While the genotypes GG vs. GC
or CC vs. GC were not statistically different in VUR vs.
controls, the genotype of GG had 4.2 times the odds of
VUR compared with the genotype of CC (95% CI of 1.14,
15.36). These data suggest that the G allele was a weak
but significant risk factor for VUR.
DISCUSSION
We have reported earlier that genetic ablation of UP
III gene in mice results in a number of striking urothelial
changes, including the conversion of the superficial cells
from squamous (umbrella) to cuboidal or even columnar
in shape. Moreover, about 50% of the UP III–deficient
mice have vesicoureteral reflux, as established by a sim-
ple Indian Ink assay and by voiding cystoureterogram
[10], a procedure used for the definitive diagnosis of VUR
in human patients. Many of these UP III–deficient mice
also have hydronephrosis, which in humans is frequently
associated with severe VUR. Similar results were ob-
tained when we recently knocked out another mouse
gene that encodes UP II—the single-transmembrane-
domained member of the other UP pair consisting of
UPII/UPIa (Kong XT, et al, in preparation). These
results demonstrate that ablation of UPs II and III can
cause VUR in mice [10, 28]. It is important to note that in
these mouse studies only homozygotes missing both UP
III alleles exhibit VUR [10]. The mechanism by which UP
deficiency causes VUR in mice is unclear. It is thought,
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Table 2. Intron-exon junctions of the human uroplakin genes
Exon/intron junctionbExona Intron
Exon Size bp Acceptor Donor Size bp
UP Ia
1 79 CATTATTCTG/gtgagactcg 1557
2 201 ctctgtccag/CTGTCAGGCC GGTCCTCACG/gtgagactcc 4577
3 75 gtctccccag/TACCTGGTGC CCGTGACTAC/gtgagcccgg 131
4 108 ttctcctcag/ATGGTGTCCA CATGATTGAG/gtgggcgggg 2294
5 180 ttcactctag/CAAGAATGCT GTTCACCAAG/gtgtggccgt 1792
6 84 ccctgcccag/GGCTGCTTCG GATGTGGACG/gtgagaggcg 79
7 491 tcctcgccag/CTCCCGGTCA
UP Ib
1 96 ctttcaacag/TGCCTTCAGC GATTATTGGT/gtaagtaatg 963
2 201 ttgcccccag/TGTTGCGGCA TCTTCTGGCG/gtaagacctc 2268
3 75 tcccttccag/TATTTCATTC ACAAGACTTT/gtgagtacaa 661
4 123 ccttttatag/TTCACACCCA CATGCTCCAG/gtaagactgt 3113
5 180 ttgctgacag/GACAATTGCT TCACAATCAG/gtgagtcctc 4657
6 84 actccttcag/GGCTGCTATG CTGCTGGACT/gtgagtattt 4775
7 1241 tctattccag/TTTTGGGTTC
UP II
1 109 ggaaccccag/CCTGCCAGCA GGGGCTGCAG/gtctcttcca 456
2 132 ctcccatcag/ACTTCAACAT GACAGCAAAG/gtctgctacc 193
3 139 ttctgcccag/TGGTGACGTC CCAAATTCTA/gtaggtactg 251
4 71 accacaaaag/CATTTCCTAC ACACTCCCTC/gtaagtaaca 428
5 463 cttttgacag/GAAGGAACAT
UP III
1 79 TTCGGCTCGG/gtaggcggtg 875
2 156 cctcctccag/CTGTGAACCT GTCGACTCAG/gtaagggtcc 1075
3 280 gcctctgcag/CCATTTCCAG CGGAGTACAG/gtgggtgtaa 1609
4 83 ctccttccag/GTTCAAGTAT ACCAACCAGC/gtaagtggtg 4037
5 133 cccaccacag/TCACCCCATA TCAGCCTCGT/gtaagtacct 2246
6 322 ccttggacag/GGACATGGGG
All introns follow the GT-AG rule except for intron 5 of uroplakin II.
aBased on GenBank accession no. AF085807 (UP Ia), AB002155 (UP Ib), NM 006760 (UP II), and NM 006953 (UP III). The first exon of each gene includes the
5′-UTR and the last exon of each gene includes the 3′-UTR.
bExon sequences are capitalized and intron sequences are in small letters.
however, that since UP expression begins quite early in
urothelium covering the entire lower urinary tract dur-
ing embryonic development (Fig. 2), UP deficiency may
lead to widespread urothelial abnormalities that in turn
affect the development of lower urinary tract leading
to VUR, possibly due to a lateral displacement of the
vesicoureteral junction [35]. Additional experiments are
being conducted to determine whether this mechanism
indeed operates in the UP-deficient mice.
To test for the possible involvement of UP defects in
VUR in human patients, we have analyzed the entire cod-
ing sequences as well as 50 to 150 bp of their flanking
noncoding/intronic sequences of the four major UP genes
from 76 VUR patients and found 18 SNPs (Table 4). Fur-
ther analysis of five of them that are missense and have
a minor frequency of >5%, as well as an SNP in the 5′-
nontranscribed region of UP III gene, showed that only
two of them, the Pro154Ala of UP III and the Ala7Val
of UP Ia, were weakly associated with VUR (Table 5).
Additional screening of the UP III SNP using another
batch of VUR patients and normal controls confirmed
a weak association (Table 5). The main conclusion from
these results is that some UP alterations, such as the ones
we identified here, may play a role, albeit a relatively mi-
nor one, in VUR (see below). Specifically, the proline
to alanine change in UP III could lead to the loss of a
“proline-kink” thus resulting in a major change in pro-
tein conformation and possibly protein stability [36–38].
Although these results indicate that UP alterations can
play a minor role in VUR, perhaps the most significant
and somewhat surprising conclusion from our data is that
major UP mutations are not found in patients with pri-
mary VUR.
Given the striking VUR and severe hydronephrosis
phenotype seen consistently in about 50% of the UP
III–deficient mice [10], and more recently, in the UP
II–knockout mice (unpublished observations), we antic-
ipated that UP defects might play a prominent role in
human VUR patients [10, 39]. Our results indicate, how-
ever, that genetic changes in UP genes are, at best, in-
volved in a minor manner in the population of VUR
patients that we have studied (Table 5). There are several
possible explanations for this apparent contradiction be-
tween the mouse and human data. First, human UP genes
may be functionally redundant. This seems unlikely, how-
ever, given the fact that the amino acid sequences of
UPs are highly conserved [11, 15], and that genetic ab-
lation of UP III and II genes yielded striking phenotypes
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Fig. 2. Expression of uroplakin (UP) in embryonic mouse (A to E) and human (F to I) urothelium. Whole-mount (A) or paraffin sections of
mouse bladder of E13 (A), E14.5 (B), E15.5 (C), and E16.5 (D), and renal pelvis of E16.5 embryos (E) were stained by immunofluorescence (A)
and peroxidase (B to E). A rabbit polyclonal antiserum against total bovine UPs (A) or a mouse monoclonal antibody to UP III (B to E) was used.
Note the strong UP staining of the apical urothelial surface not only in the bladder (A to D), but also in ureter and renal pelvis (E). Human fetal
bladder at 70 days’ gestation was paraffin-sectioned and stained using a rabbit antiserum to total bovine UPs (F and G) and a rabbit antiserum
against UP Ib (H and I). (G and I) The higher magnification views of (F and H), respectively. All sections, except the whole mount in (A), were
counterstained with hematoxylin. Note the strong immunostaining of the luminal surface of the fetal human bladder urothelium.
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Table 3. Primers used for amplifying the exons and flanking intron regions of human uroplakin (UP) genes
Exon Size bp Forward primer (5′→3′) Reverse primer (5′→3′)
UP Ia
1 450 GGAGTCTGGGTATGGCATGAGa TGAGTCTGCCCGAGAGACAGT
2 426 GGTCTTTGCCCACTTTACTGAa GGAACTCACACTAGTGGCTGG
3 287 AAACTTGCATTTCCCCAGTG GGAGAACAGGGAAGAACAAGGa
4 271 CGGAGGTCGTCCTCTCTCC GAGATCTCATGAGCGGATGTCa
5 323 CAGCTGTGTCAAAGGCCAATCCTGa GATGGATAGACAGATGGAGCAGGGC
6, 7 438 CTCAGGGAAGGTGGTGACTTTa AGTGGAAGGACGTAAGGGCTA
UP Ib
1 473 AGTCCACCACTCAGAAGGATG AGGAAGCCAGTAATCACAGCATa
2 480 CTGGCAATGGGGAGTTTAGAa CATGTGGACCATTTCACTGC
3 320 CTAGCACCAAGCCTCAATCC TGCCTGGGCACATAGTAAGGa
4 363 CGCCTCTGAGTACAGTTTTGCa AAGCTAATCATCATGGCTTGAA
5 405 TGGCTCTAGTAGGGACCACGa TCCTGGTTTAGCATTTGCAG
6 230 AACCAGTGGCACTCTCAAGG CCTGCTTTCCCATCAATCTCa
7 314 GCCTGAATGAACCTAACATCCACa CATGAGAACTGCAGAAGCCTG
UP II
1 466 CAGGAACACTGCCTTATGCACG AGACCTCTCTTTGAGAGCCCTGGa
2 310 CTGGTGGTCATACTGGCACAa GGGACTAGAGGGATGCCTTGG
3 262 CCTGGGGTACCCACACTCTAa CTTCCCTAGGTGCCTCAGGCT
4 277 GCCCCTCTTCCTGTAAGYCa GGTTCCGTGCTAGGATAGAGG
5 286 GTGGTCTCCCCTCTCTTTTG AGAGGAGGGCAGGAGGAGa
UP III
1 839 GAACCGAAGGGGTCATACTAGGCGTa CTGGGGCTAGTCCCTTCTCTGTCCTa
2 344 CACGTGCTCAGTAACTGCAAGa ATGAGACGACTACAGGCATGG
3 456 AGGATGATCAGGCATTTGATG CAAGAAGTGTGGCTGCTCCTAa
4 217 ACCCCTAGGCCATCCTACATCCC CCTTCTCGGGTCCCCTTGAGCATCa
5 258 GTGCGGTGTCTGGGAAGTAAC GAGGACCCCACTGCTGAGTCa
6 349 AAGGCATTTGGGTTTGCTCTa AAGGGTTTTCCTGCAGTTGGA
aPrimers used for DNA sequencing reactions.
Table 4. Variations and allelic frequency of the human uroplakin (UP) genes from 76 vesicoureteral reflux (VUR) patients
Frequency %
SNP Location Positiona Common Variant VUR control
UP Ia
1 Exon 1 21 GCC (Ala7) GTC (Val) 10.5 15.6
2 Exon 2 92 TCC (Ser31) GCC (Ala) 9.9 11.7
3 Exon 2 94 TCC (Ser31) TCT (Ser) 0.7
4 Exon 3-5′ acceptor [−26] G T 8.7
5 Exon 7 753 TAT (Tyr251) TTT (Phe) 1.5
TAT (Tyr251) TGT (Cys) 1.5
6 Exon 7 765 ATG (Met255) ACG (Thr) 42.8 46.7
UP Ib
1 Exon 3 345 CGA (Arg113) CAA (Gln) 6.6 6.7
UP II
1 Exon 3 254 ACG (Thr72) ACA (Thr) 0.8
2 Exon 5 592 TAA (Stop) TGA (Stop) 14.8
UP III
1 5′ UTR [−73] G A 25.7 17.2
2 5′ UTR [−25] G C 2.9
3 Exon 2-3′ donor 84 C A 1.4
4 Exon 3-5′ acceptor [−17] C G 5.1
5 Exon 3 272 CAA (Gln91) CTA (Leu) 0.7
6 Exon 3 402 GTC (Val134) GTT (Val) 22.4
7 Exon 3 460 CCA (Pro154) GCA (Ala) 25.0 15.6
8 Exon 4 549 TCA (Ser183) TCG (Ser) 35.9
9 Exon 6 858 CAA (Gln286) CAG (Gln) 43.5
VUR is vesicoureteral reflux. The number of single nucleotide polymorphisms (SNPs) detected in UP genes varied significantly. UP Ib and UP II genes contained
only one and twp SNPs, respectively, while UP Ia and III genes contained six and nine SNPs, respectively. Thus, the SNP density ranged from one SNP per 2.2 kb for Ib
to one per 233 bp for III, with an average of one SNP per ∼410 bp. Twelve of the 18 SNPs resided in the coding regions, with only six in the noncoding regions; thus the
SNP density of the coding regions was 3.5-fold higher than that of the noncoding regions.
aBased on GenBank accession nos. AF085807 (UP Ia), AB002155 (UP Ib), NM 006760 (UP II), and AB010637 (UP III).
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Table 5. Case-controlled analysis of the association between vesicoureteral reflux (VUR) and uroplakin (UP) polymorphisms
Single nucleotide Vesicoureteral Control
polymorphism Genotype reflux number (%) number (%) P valuea Odds ratio 95% CI limits
UP Ia 1 CC 63 (82.9) 64 (71.1) 0.08 CC vs. CT 2.38 1.69, 5.55
(Ala7Val C->T) CT 10 (13.1) 24 (26.7) CC vs. TT 0.28 0.04, 1.9
TT 3 (4) 2 (2.2) TT vs. CT 3.6 0.52, 24.93
UP Ia 2 GG 4 (5.3) 2 (2.2) 0.13 GG vs. GT 4.76 0.72, 33.3
(Ser31Ala T->G) GT 7 (9.2) 17 (18.9) GG vs. TT 2.17 0.38, 12.5
TT 65 (85.5) 71 (78.9) TT vs. GT 2.22 0.87, 5.7
UP Ia 6 CC 17 (22.4) 19 (21.1) 0.36 CC vs. CT 1.33 0.59, 2.94
(Met255Thr T->C) CT 32 (40.8) 46 (51.1) CC vs. TT 0.8 0.34, 1.88
TT 28 (36.8) 25 (27.8) TT vs. CT 1.66 0.86, 3.37
UP Ib 1 AA 0 (0) 0 (0) 0.97
(Arg113Gln G->A) AG 10 (13.2) 12 (13.3)
GG 66 (86.8) 78 (86.7) GG vs. AG 1.01 0.41, 2.5
UP III 1 AA 6 (7.9) 3 (3.3) 0.19 AA vs. AG 1.85 0.42, 8.33
(−73 G->A) AG 27 (35.5) 25 (27.8) AA vs. GG 2.8 0.68, 12.5
GG 43 (56.6) 62 (68.9) GG vs. AG 0.64 0.33, 1.25
UP III 7 GG 7 (9.2) 2 (2.2) 0.08 GG vs. GC 3.5 0.65, 18.1
(Pro154Ala C->G) GC 24 (31.6) 24 (26.7) GG vs. CC 4.98 0.98, 25.08
CC 45 (59.2) 64 (71.1) CC vs. GC 0.7 0.36, 1.39
UP III 7 (batch 2) GG 8 (4.8) 1 (1.7) 0.37 GG vs. GC 2.44 0.28, 20.84
GC 59 (35.3) 18 (30) GG vs. CC 3.28 0.39, 27.1
CC 100 (59.9) 41 (68.3) CC vs. GC 0.74 0.39, 1.4
UP III 7 GG 15 (6.2) 3 (2) 0.036b GG vs. GC 3.02 0.8, 11.4
(batch 1 and batch 2b) GC 83 (34.2) 42 (28) GG vs. CC 4.2 1.14, 15.36
CC 145 (59.6) 105 (70) CC vs. GC 0.73 0.45, 1.16
aChi-square test for association; bMantel-Haenszel chi-square test for general association.
including VUR and hydronephrosis [10, 28]. Second, only
one healthy allele of UP gene may be functionally ade-
quate. This may be particularly true if the mutation makes
the UP less efficient in interacting with other UPs; if so
the UP encoded by the remaining “healthy” allele would
be functional while the mutated UP would be excluded
from interacting with other UPs and thus would be in
effect silent. This may be the case for the Pro154Ala mu-
tation of UP III, which is expected to introduce a major
change in protein conformation [36, 37]. Third, the al-
tered UP conformation may be “corrected” and thus tol-
erated once the mutant protein is incorporated into the
presumably tightly packed UP complex [21, 40]. In this
regard, it is known that the extracellular domains of UPs
interact with one another tightly in forming the 16 nm par-
ticle, such that many of the antigenic epitopes defined by
synthetic peptides become inaccessible in intact urothe-
lial plaques [25]. Fourth, we have found that, although
some of the breeding pairs that we used to generate the
UP III−/− homozygote offspring yielded litters that can
survive into adulthood despite their VUR and associated
hydronephrosis, some other breeding pairs yielded off-
spring that consistently die around days 8 to 10 postna-
tally, with elevated blood urea nitrogen suggesting renal
failure [10]. In additional, we recently found that some of
the breeding pairs of UP II knockout mice also yielded
litters that underwent similar VUR, renal abnormalities,
and neonatal death (unpublished). These results suggest
that a major UP defect, when combined with a certain
genetic background, can be neonatally lethal in mice. In
this regard it is important to note that, in humans, uri-
nary tract malformations are among the most common
of all congenital anomalies, and are principal reasons for
both medically indicated terminations of pregnancy and
also can cause fetal, perinatal, and infant death [41, 42].
This raises the interesting possibility that major human
UP defects may also cause renal and other abnormali-
ties resulting in prenatal or postnatally lethality; such a
possibility could explain why we have not encountered
major UP defects, including truncation and frame-shift,
in our VUR analysis. Fifth, although our data cannot
rule out the possibility that causative mutations in the
intronic sequences that are destroyed in the knockout
mice are responsible for the observed mouse phenotype,
our current data suggest that missense changes of UP
genes cannot play a dominant role in causing VUR in
human since we found only a weak association between
UP mutations and VUR phenotype, a lack of significant
mutations in the 50 to 150 bp flanking introns, and, impor-
tantly, a lack of families with simple dominant Mendelian
inheritance (unpublished observation). Additional stud-
ies are needed, however, to address whether mutations in
5′- and/or 3′-noncoding genomic sequences, as well as in-
tronic sequences that are not covered in our current study
but can potentially cause diseases [43], play a contribut-
ing role in VUR. Finally, and perhaps most important,
our data are consistent with the hypothesis that VUR is a
complex and heterogeneous symptom that can be caused
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by a large number of genetic defects that affect multi-
ple cell types in the lower urinary tract. Nishimura et al
[44] showed that a large portion of mice lacking the an-
giotensin type 2 receptor (AT2R) gene exhibited VUR
while a smaller percentage also exhibited other congeni-
tal anomalies, including megaureter, ureteral duplication,
and multicystic dysplastic kidneys [44]. However, a small
scale survey of 23 VUR patients suggest that defects in the
AT2R gene may not be involved in VUR [45]. This situa-
tion is therefore analogous to ours and suggests that mu-
tations in AT2R and UPs may be involved in only small
subpopulations of human VUR patients. The heterogene-
ity of human VUR is strongly supported by Feather et al
[9] who studied, by genome-wide search, seven European
families whose members exhibit apparently dominant in-
heritance of VUR. This study identified in one of the
pedigree a positive locus on chromosome 1p13, which
clearly could not be related to the four major UP genes
(Table 1) and was not involved in other pedigrees [9].
Overall, our results are consistent with the idea that
VUR is a heterogeneous disease that is caused by defects
in a panel of genes that are expressed in the lower urinary
tract. Knockout mice lacking such genes provide well-
defined and valuable experimental models for studying
certain aspects of VUR. However, statistical analysis of
a general population of VUR patients may mask the in-
volvement of individual genes in such a heterogeneous
disease. Genome-wide search using large pedigrees of
VUR [9], coupled with association studies [46], is needed
to pinpoint genetic defects, which could include those of
UP and AT2R genes, that underlie the VUR phenotype
within specific pedigrees.
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